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Introduction
A decrease in brain glucose metabolism in Alzheimer’s disease (AD) patients is considered a critical driver of cognitive impairment, and medications used in AD target this metabolic 
dysfunction. Recent evidence has shown a significant increase in glucose metabolism associated with neurocognitive improvement after intrathecal administration of bone marrow 
mesenchymal stromal cells (MSCs) in patients suffering from severe TBI or haemorrhagic stroke. We hypothesise that this cell therapy could also be useful in AD patients. 
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Image 1: 
VSTMB Test: It requires subjects to detect whether or not two combinations of shape 
and colour change across two sequential arrays.
Changes in 18F-FDG-PET in case 1 and case 2 from Vaquero et al, 2019.
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This task has 
been proposed as 
a preclinical marker 
of AD.
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Case 1. A-C: beta-amyloid neuritic plaques with 
18F-Flutemetamol-PET.
D-E: 18F-FDG-PET previous to cell therapy and 
one week after first intrathecal administration of 
100 millions MSCs (G-I).
Case 2. 18F-FDG-PET 
showing metabolic activity 
previous to cell therapy (A-C) 
and at the end of treatment (D-
F).
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• Participants:
• N=2
• Diagnosis of Alzheimer’s disease. 
• Without medication
• Detection of beta-amyloid neuritic plaques  (18F-
Flutemetamol-PET).
• Brain glucose metabolism studied with 18F-FDG-
PET
• Clinical procedures and experimental task:
Intrathecal cell therapy with autologous MSCs increases cerebral glucose metabolism, being associated with neuropsychological improvements in patients experiencing early stages of 
AD. This type of cell therapy is safe, allowing distribution of donor cells in the whole brain, and its utility for the treatment of AD and other diseases with cerebral impaired glucose 
metabolism deserves further studies. Administration of autologous MSCs should be considered as a new therapeutic strategy for Alzheimer’s dementia and deserves further studies. 
Conclusions
Caracteristics
• Neuropsychological assessment:
Neuropsychological and functional assessment
Mini Mental State Examination (MMSE) Addenbrooke’s Cognitive Examination 
Rey Complex Figure Test Barthel ADL Scale
Stroop test Lawton & Brody IADL Scale 
TAVEC (Spanish adaptation to CVLT) Clinical Dementia Rating
Wechler Adult Intelligence Scale (WAIS-III)
STMB TASK PRE POST 1 POST 2 POST 3 POST 4 POST 5
Shape Only 100% 100% 94% 100% 100% 91%
Shape-Colour
Binding
50% 62% 66% 62% 67% 81%
STMB TASK PRE POST 1 POST 2 POST 3
Shape Only 88% 91% 88% 88%
Shape-Colour
Binding
52% 69% 66% 81%
The chance that an untreated AD patient would show more impairment than treated patients was 39.25% (p= 0.785) for case 1, and 50.00% (p=1.0) for 
case 2. This chance increased post-treatment to 97.40% (p=0.05) and 99.74% (p=0.005) respectively.
